Q-omics provides the consensus-scored BCDIN3D profile across patient tissues and cancer cell-line models. BCDIN3D expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BCDIN3D is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, BCDIN3D RNA expression shows 19,917 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where BCDIN3D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCDIN3D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCDIN3D survival associations across molecular data types. BCDIN3D RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCDIN3D RNA expression–survival associations across cancer types. High BCDIN3D expression shows unfavorable associations in UVM and LIHC, but favorable associations in KIRC, UCEC, BRCA and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BCDIN3D RNA expression.
This table summarizes BCDIN3D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for BCDIN3D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCDIN3D shows lower tumor expression in THCA and higher tumor expression in LIHC, BRCA, CHOL, PRAD and BLCA. The THCA box plot shows higher BCDIN3D RNA expression in normal versus tumor tissue (log2 FC = −1.109, t-test p < 0.001).
This table shows molecular features associated with BCDIN3D in patient tissues and cancer cell lines. In patient samples, BCDIN3D shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BCDIN3D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
